Deep Genomics (AI) — Funding, Investors & Signals 2026

Deep Genomics

Founded 2014 Canada

Toronto, Canada 109 employees Series C Total: $236.70M AI, Biotechnology +1

Deep Genomics, founded in 2014 and headquartered in Canada, operates at the forefront of AI, Biotechnology, and Health and Wellness. The company is revolutionizing drug discovery by developing the Biological Foundation (BioFM) Model Platform, designed to enhance molecular design and target biology, areas traditionally reliant on empirical iteration.

The BioFM Model Platform merges AI model development with lab-in-the-loop workflows, providing cutting-edge screening technologies and datasets. This common architecture enables Deep Genomics to identify elusive molecules and targets, streamlining and accelerating their development into transformative medicines for patients.

In its latest financial milestone, Deep Genomics secured a $180.00M Series C investment on 28 July 2021, backed by notable investors such as CPP Investments, Khosla Ventures, True Ventures, Magnetic Ventures, Alexandria Venture Investments, Amplitude Ventures, Fidelity, and SoftBank Vision Fund.

Funding Stage	Amount	Investors	Lead Investors	Date
Series C	$180.00M	8	CPP Investments, Khosla Ventures +6	28 Jul 2021
Series B	$40.00M	6	Future Ventures, Khosla Ventures +4	07 Jan 2020
Series A	$13.00M	3	Khosla Ventures, True Ventures +1	25 Sep 2017
Seed Round	$3.70M	3	Bloomberg Beta, 11.2 Capital +1	18 Nov 2015
Non Equity Assistance	Undisclosed	1	Creative Destruction Lab	02 Oct 2015
Pre Seed Round	Undisclosed	1	UTEST	01 Jan 2015

Funding Stage

Amount

Investors

Lead Investors

Date

Series C

$180.00M

CPP Investments, Khosla Ventures +6

28 Jul 2021

Series B

$40.00M

Future Ventures, Khosla Ventures +4

07 Jan 2020

Series A

$13.00M

Khosla Ventures, True Ventures +1

25 Sep 2017

Seed Round

$3.70M

Bloomberg Beta, 11.2 Capital +1

18 Nov 2015

Non Equity Assistance

Undisclosed

Creative Destruction Lab

02 Oct 2015

Pre Seed Round

Undisclosed

UTEST

01 Jan 2015

FAQ About Deep Genomics

Deep Genomics collaborates across disciplines to solve hard molecular design and target biology problems historically requiring slow, empirical iteration. We can do this because of our Biological Foundation (BioFM) Model Platform - a single engine with lab-in-the-loop workflows, AI model developmen...

Deep Genomics was founded in 2014.

Deep Genomics is headquartered in Toronto, Canada.

Deep Genomics operates in AI, Biotechnology and Health and Wellness. Its work centres on genetic therapies, biology, genomics and drug development. Its customers include pharmaceutical companies, biotechnology researchers and medical scientists.

Deep Genomics has a Platform, B2B and PaaS business model. Its revenue comes from Licensing, Performance Based and Subscription.

Deep Genomics has approximately 109 employees.

Deep Genomics has completed 6 funding rounds, raising a total of $236.70M. The latest funding stage is Series C.

Deep Genomics offers: AI model refinement, molecular target identification, drug development acceleration, data asset generation, software systems for biotech.

Top alternatives and competitors to Deep Genomics include Mosaic TX, Aro Biotherapeutics, KSQ Therapeutics, Inc., Tavros Therapeutics, Orna Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Deep Genomics and Mosaic TX are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Deep Genomics

General Information

Discover More

About Deep Genomics

Services & Products

Target Customers

Funding Rounds & Investors (6)

Deep Genomics Alternatives & Competitors

FAQ About Deep Genomics